You are here: Industry Insights > 2024

News List

Avantor Triumphs with Three Awards at Korea Biopharma Excellence Awards 2024 PharmaSources
August 26, 2024
Avantor, Inc. has secured three prestigious awards at the esteemed Korea Biopharma Excellence Awards (KBEA) 2024.
InnoCare Releases 2024 Interim Results and Business Highlights August 21, 2024
InnoCare Pharma announced the 2024 interim results and corporate update as of 30 June 2024.
Popular Products and Companies at PharmaSources.com (June 2024) PharmaSources
June 25, 2024
Popular Products and Companies at PharmaSources.com
Pharma Sources Insight June 2024: Globalization on the GO! Pharma Sources Insight
June 29, 2024
Pharma Sources Insight JUNE 2024 focuses on wearable delivery system, sythetic biology, pharmaceutical globalization and more.
Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress PharmaSources
June 14, 2024
Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2024 Hybrid Congress.
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress PharmaSources
June 05, 2024
Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
Vetter Wins Best Managed Companies Award 2024 PharmaSources
May 30, 2024
Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), has once again been awarded the Best Managed Companies Award, marking its fifth consecutive win.
2024 Medical Breakthroughs: New Hope to Patients Shruti Talashi
April 11, 2024
The pharmaceutical industry is set for a major shake-up in 2024.
Avantor Wins Five Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2024 PharmaSources
March 21, 2024
Recognition reinforces Avantor's commitment to innovation and leadership for biopharma advancement.
Latest data of InnoCare's ICP-332 for the Treatment of Atopic Dermatitis Presented at LBA Session of 2024 AAD Chunhua Lu
March 11, 2024
Efficacy and Safety of a Highly Selective Oral TYK2/JAK1 Inhibitor, ICP-332, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II, Randomized, Placebo-Controlled Trial.